reference/2441876

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/2441876

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	4618
issn	0006-4971 1528-0020
issueIdentifier	20
pageRange	4614-4618
publicationName	Blood
startingPage	4614
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ab80a732b5df33e85751c0a758afb577
bibliographicCitation	Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17;119(20):4614–8. PMID: 22422826; PMCID: PMC4081383.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9f47d0d361f161cb351e9f872c0395e6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d385488543f34cbcb03937beec35fe5c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_83ca8b9cc3e60802996f1f6f5c201ebb http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d364474d375c00a5173abc2ddf6434c0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f89be6c894deba4e08e75140e5b8bf12 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4661341a5ab822da5a6e54d7665f2d45 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5bf46ae2f667749b0a849d318a692dc3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9d486b0352524567a03a648ed075996a http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8636-1071 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5129d9203aab04576f5d0fe77808249b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c8c1de7da4deb440ed2ecc8697edce38 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4190883552be9e16fc03bddc09e5f0ec http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b6d00d3aba027043e0cfebb59b17c883 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ca6dfaf773dc1915e94d956a62963b36 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b010671c2d90c083d5256b16afb62beb
date	2012-05-17^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC4081383 https://doi.org/10.1182/blood-2011-12-400051 https://pubmed.ncbi.nlm.nih.gov/22422826
isPartOf	https://portal.issn.org/resource/ISSN/1528-0020 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1243 https://portal.issn.org/resource/ISSN/0006-4971
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
discusses	http://id.nlm.nih.gov/mesh/M0473784 http://id.nlm.nih.gov/mesh/M0477916 http://id.nlm.nih.gov/mesh/M0018226 http://id.nlm.nih.gov/mesh/M0495016 http://id.nlm.nih.gov/mesh/M0018260 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0457532 http://id.nlm.nih.gov/mesh/M0549299 http://id.nlm.nih.gov/mesh/M0203030 http://id.nlm.nih.gov/mesh/M0229085 http://id.nlm.nih.gov/mesh/M0014878
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D015470Q000188 http://id.nlm.nih.gov/mesh/D009196Q000188 http://id.nlm.nih.gov/mesh/D011720Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D012008 http://id.nlm.nih.gov/mesh/D009570 http://id.nlm.nih.gov/mesh/D050796Q000378 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D000970Q000627 http://id.nlm.nih.gov/mesh/D010766Q000187 http://id.nlm.nih.gov/mesh/D053614Q000235 http://id.nlm.nih.gov/mesh/D011743 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D009196Q000473 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D019008Q000187 http://id.nlm.nih.gov/mesh/D019008Q000235 http://id.nlm.nih.gov/mesh/D020125Q000502 http://id.nlm.nih.gov/mesh/D047428Q000627 http://id.nlm.nih.gov/mesh/D053612Q000037 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D015470Q000473 http://id.nlm.nih.gov/mesh/D047428Q000009 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D053612Q000235 http://id.nlm.nih.gov/mesh/D018450 http://id.nlm.nih.gov/mesh/D011720Q000009
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f1b19ffd977e0a98cd78708658634390 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9731 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25126798 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8300

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID248273374

Showing number of triples: 1 to 83 of 83.